Olive oil supplementation during cardiac rehab for heart failure with reduced ejection fraction

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this interventional study, adults with heart failure and an ejection fraction of 35% or less will receive daily extra-virgin olive oil for 12 weeks while participating in standard cardiac rehabilitation. The goal is to assess feasibility and see if EVOO can improve functional capacity and quality of life. Participants must be referred to and not yet started in the rehabilitation program, with specific exclusions to ensure safety. The study is led by Old Dominion University at the Strelitz Diabetes Center in Norfolk, Virginia, with no listed collaborators.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with HFrEF with left ventricular ejection fraction ≤35 %.
* Referred to and enrolled in the standard cardiac rehabilitation program at Sentara Cardiac Rehabilitation Center, but has not yet initiated/started cardiac rehabilitation (i.e., has not attended the first cardiac rehab session).
* Able and willing to comply with study procedures and provide informed consent.

Exclusion Criteria:

* Co-morbidity expected to limit survival (e.g., terminal illness).
* End-stage renal disease.
* Unstable fluid overload.
* Current pregnancy (self-disclose).
* Habitual use of EVOO greater than 4 tablespoons per day.
* Known allergy or sensitivity to olive oil or its components.
* Unwillingness or inability to incorporate EVOO or dietary recommendations.

Where it's running

• Strelitz Diabetes Center (Williams Hall)
  Norfolk, Virginia, United States Recruiting

Study contacts

• Principal investigator: Salvatore Carbone, PhD, RDN — Macon & Joan Brock Virginia Health Sciences at Old Dominion University
• Study coordinator: Salvatore Carbone, PhD, RDN
• Email: scarbone@odu.edu
• Phone: 757-446-7149

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Atrial Shunt to Help Heart Failure With Reduced Ejection Fraction

  This study tests whether an atrial shunt implanted after heart catheterization helps people with HFrEF when added to standard heart failure therapy.

  Recruiting Phase 2/3 Beijing Anzhen Hospital · Beijing, Beijing Municipality · NCT07820410

• Achieving Optimal Medical Therapy Through Transcatheter Mitral Repair in HFrEF

  This trial tests whether early transcatheter edge-to-edge repair (M-TEER) helps patients with HFrEF and secondary MR reach guideline-directed medical therapy faster and more completely, and whether that improves quality of life and outcomes.

  Recruiting University Medical Center Mainz · Mainz, Rhineland-Palatine · NCT07758023

• CRD-4730 for heart failure with reduced ejection fraction

  This trial tests CRD-4730 versus placebo to see if it helps adults with HFrEF who are already on standard heart failure therapy.

  Recruiting at 2 sites Phase 2 Cardurion Pharmaceuticals, Inc. · Pasadena, California and 1 other locations · NCT07750873

• Remote-guided medication up-titration for people with reduced ejection fraction heart failure

  This trial will see if telemedicine follow-up helps clinicians start and increase guideline-recommended heart failure medicines faster and more completely in adults with newly diagnosed HFrEF.

  Recruiting Azienda Unita Sanitaria Locale di Piacenza · Piacenza · NCT07518030

• Vericiguat for right‑ventricular function and heart remodeling in HFrEF

  This study will test whether adding vericiguat to usual heart‑failure treatment helps adults with stable HFrEF improve right‑ventricular function and heart remodeling over 12 months.

  Recruiting at 4 sites Phase 4 University Medical Centre Ljubljana · Izola and 3 other locations · NCT07405944

• Nerve ablation for heart failure with reduced ejection fraction using the right greater splanchnic nerve

  This early-stage, catheter-based test looks at whether ablating the right greater splanchnic nerve can help people 40 and older with HFrEF and is done in a randomized, sham-controlled setup.

  Recruiting at 7 sites Axon Therapies, Inc. · Prague and 8 other locations · NCT07403058

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.